Dr. Paul Ridker and Dr. C Michael Gibson Discuss: Thirty-year cardiovascular outcomes in women based on C-reactive protein, LDL cholesterol, and lipoprotein(a) August 31, 2024 Disclosures: TBD
Dr. Johanne Silvain, Dr. Gilles Montalescot and Dr. C Michael Gibson Discuss: ABYSS – Beta blocker interruption in post-myocardial infarction patients August 30, 2024 Disclosures: TBD
Dr. Mikhail Kosiborod and Dr. C Michael Gibson Discuss: Effects of semaglutide on clinical events in heart failure with preserved ejection fraction: a pooled, participant-level analysis of SELECT, FLOW, STEP-HFpEF and STEP-HFpEF DM trials August 30, 2024 Disclosures: TBD
Dr. Jim Udelson, Dr. Sanjiv Shah, and Dr. C. Michael Gibson Discuss: The take home lessons from the RELIEVE HF study and the path forward View Video April 25, 2024 Disclosures: TBD
Dr. Leslie Cho and Dr. C. Michael Gibson Review: Multiple analyses from the Clear Outcomes Study presented at ACC 2024 including those regarding Gender, Hispanic and Obesity s/b Esperion April 19, 2024 Disclosures: TBD
Dr. Moritz Seiffert and Dr. C. Michael Gibson Discuss: Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement In Patients At Low To Intermediate Risk: One Year Outcomes Of The Randomized DEDICATE-DZHK6 Trial April 19, 2024 Disclosures: TBD
Dr. Jung-Min Ahn, Dr. Duk-Woo Park and Dr. C. Michael Gibson Discuss: Preventive PCI Or Medical Therapy Alone For Atherosclerotic Coronary Vulnerable Plaques April 8, 2024 Disclosures: TBD
Dr. David Kandzari and Dr. C. Michael Gibson Discuss: Effect Of Alcohol-mediated Renal Denervation On Blood Pressure In The Presence Of Antihypertensive Drugs: 3-month Primary Results From The Target Bp I Randomized Trial April 8, 2024 Disclosures: TBD
Dr. Rasha Al-Lamee, Dr. Michael Foley and Dr. C. Michael Gibson Discuss: Coronary Sinus Reducer For The Treatment Of Refractory Angina: A Randomised, Placebo-controlled Trial (ORBITA-COSMIC) April 8, 2024 Disclosures: TBD
Dr. David Austin and Dr. C. Michael Gibson Discuss: Preventing Cardiac Damage In Patients Treated For Breast Cancer And Lymphoma: A Phase 3 Randomized, Open Label, Blinded Endpoint, Superiority Trial Of Enalapril To Prevent Anthracycline-induced Cardiotoxicity (PROACT) April 8, 2024 Disclosures: TBD
